Since the original description of amyloid-β plaques and tau tangles more than 100 years
ago, these lesions have been considered the neuropathological hallmarks of Alzheimer …

Abstract Alzheimer's disease (AD), the most common form of dementia worldwide, is a mixed
proteinopathy (β-amyloid, tau and other proteins). Classically defined as a …

Alzheimer's disease (AD) is a progressive neurodegenerative disease, which has brought a
huge burden to the world. The current therapeutic approach of one-molecule-one-target …

Many potential immune therapeutic targets are similarly affected in adult-onset
neurodegenerative diseases, such as Alzheimer's (AD) disease, Parkinson's disease (PD) …

Alzheimer's dementia is a pathologically heterogeneous and biologically multilayered
disease. Recent studies and exercises in nomenclature reveal shortcomings in existing …

Alzheimer's disease and cerebral small vessel disease are the two leading causes of
cognitive decline and dementia and coexist in most memory clinic patients. White matter …

The recent commercialisation of the first disease-modifying drugs for Alzheimer's disease
emphasises the need for consensus recommendations on the rational use of biomarkers to …

The most frequent reason of morbidity and mortality in the world, cerebral ischemia sets off a
chain of molecular and cellular pathologies that associated with some central nervous …

Hereditary ataxias, especially when presenting sporadically in adulthood, present a
particular diagnostic challenge owing to their great clinical and genetic heterogeneity …

Alzheimer disease (AD) is currently the leading cause of cognitive decline and dementia
worldwide. Recently, studies have suggested that other neurodegenerative comorbidities …